EUVIMEDEUVIMED entdecken
Crossref

Capturing the Range of Disease Involvement in Localized Scleroderma: The Localized Scleroderma Total Severity Scale

Suzanne C Li iD, C Egla Rabinovich, Mara L Becker, Kathryn S Torok, Polly J Ferguson, Fatma Dedeoglu iD, Sandy Hong, Vidya Sivaraman, Ronald M Laxer, Katie Stewart, Maria F Ibarra, Thomas Mason und 6 weitere

Arthritis Care & Research · 2024

DOI: 10.1002/acr.25281 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis Care & Research, 2024. Verfasst von Suzanne C Li und 17 weiteren Autor:innen. Beteiligte Einrichtung: Joseph M. Sanzari Children's Hospital, Hackensack, and Hackensack Meridian School of Medicine, Nutley, New Jersey. Hauptthemen laut MEDLINE: Scleroderma, Localized, Severity of Illness Index, Scleroderma, Systemic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: ARTHFN, NIH HHS, AF.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Juvenile localized scleroderma (jLS) is a chronic autoimmune disease commonly associated with poor outcomes, including contractures, hemiatrophy, uveitis, and seizures. Despite improvements in treatment, >25% of patients with jLS have functional impairment. To improve patient evaluation, our workgroup developed the Localized scleroderma Total Severity Scale (LoTSS), an overall disease severity measure.

Methods

LoTSS was developed as a weighted measure by a consensus process involving literature review, surveys, case vignettes, and multicriteria decision analysis. Feasibility was assessed in larger Childhood Arthritis and Rheumatology Research Alliance groups. Construct validity with physician assessment and inter‐rater reliability was assessed using case vignettes. Additional evaluation was performed in a prospective patient cohort initiating treatment.

Results

LoTSS severity items were organized into modules that reflect jLS disease patterns, with modules for skin, extracutaneous, and craniofacial manifestations. Construct validity of LoTSS was supported by a strong positive correlation with the Physician Global Assessment (PGA) of severity and damage and weak positive correlation with PGA‐Activity, as expected. LoTSS was responsive, with a small effect size identified. Moderate‐to‐excellent inter‐rater reliability was demonstrated. LoTSS was able to discriminate between patient subsets, with higher scores identified in those with greater disease burden and functional limitation.

Conclusion

We developed a new LS measure for assessing cutaneous and extracutaneous severity and have shown it to be reliable, valid, and responsive. LoTSS is the first measure that assesses and scores all the major extracutaneous manifestations in LS. Our findings suggest LoTSS could aid assessment and management of patients and facilitate outcome evaluation in treatment studies. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Scleroderma, LocalizedSeverity of Illness IndexScleroderma, SystemicHumansFemaleMaleChildReproducibility of ResultsAdolescentFeasibility StudiesProspective StudiesConsensusObserver Variation

Autor:innen und Institutionen

  • Joseph M. Sanzari Children's Hospital, Hackensack, and Hackensack Meridian School of Medicine, Nutley, New Jersey.
  • Duke University School of Medicine, Durham, North Carolina.
  • University of Pittsburgh, Pittsburgh, Pennsylvania.
  • University of Iowa Carver College of Medicine, Iowa City.
  • Boston Children's Hospital, Boston, Massachusetts.
  • University of Iowa Stead Family Children's Hospital, Iowa City, Iowa.

ORCID-Profile: Suzanne C Li, Fatma Dedeoglu, Tara Lozy

Förderung

  • ARTHFN
  • NIH HHS
  • AF
  • NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • NIH
  • DCRI

Zitieren

APA

Li, S. C., Rabinovich, C. E., Becker, M. L., Torok, K. S., Ferguson, P. J., Dedeoglu, F., Hong, S., Sivaraman, V., Laxer, R. M., Stewart, K., Ibarra, M. F., Mason, T., Higgins, G., Pope, E., Li, X., Lozy, T., Fuhlbrigge, R. C., & CARRA Registry Investigators (2024). Capturing the Range of Disease Involvement in Localized Scleroderma: The Localized Scleroderma Total Severity Scale. Arthritis Care & Research. https://doi.org/10.1002/acr.25281

Vancouver

Li SC, Rabinovich CE, Becker ML, Torok KS, Ferguson PJ, Dedeoglu F, et al. Capturing the Range of Disease Involvement in Localized Scleroderma: The Localized Scleroderma Total Severity Scale. Arthritis Care & Research. 2024. doi:10.1002/acr.25281

BibTeX
@article{Li2024,
  author = {Li, Suzanne C and Rabinovich, C Egla and Becker, Mara L and Torok, Kathryn S and Ferguson, Polly J and Dedeoglu, Fatma and Hong, Sandy and Sivaraman, Vidya and Laxer, Ronald M and Stewart, Katie and Ibarra, Maria F and Mason, Thomas and Higgins, Gloria and Pope, Elena and Li, Xiaohu and Lozy, Tara and Fuhlbrigge, Robert C and CARRA Registry Investigators, CARRA Registry Investigators},
  title = {Capturing the Range of Disease Involvement in Localized Scleroderma: The Localized Scleroderma Total Severity Scale},
  journal = {Arthritis Care & Research},
  year = {2024},
  doi = {10.1002/acr.25281}
}
Kostenlos starten →